These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 30189922)
1. H727 Multicellular Spheroids and Its Resistance to Antitumor Drugs Sunitinib and Axitinib. Wang Z; Chen H; Zhou N; Zhang T; Ren P; Chen G J Nanosci Nanotechnol; 2018 Dec; 18(12):8078-8084. PubMed ID: 30189922 [TBL] [Abstract][Full Text] [Related]
2. Real-time viability and apoptosis kinetic detection method of 3D multicellular tumor spheroids using the Celigo Image Cytometer. Kessel S; Cribbes S; Bonasu S; Rice W; Qiu J; Chan LL Cytometry A; 2017 Sep; 91(9):883-892. PubMed ID: 28618188 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Miyazaki A; Miyake H; Fujisawa M Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115 [TBL] [Abstract][Full Text] [Related]
4. Human neuroendocrine tumor cell lines as a three-dimensional model for the study of human neuroendocrine tumor therapy. Wong C; Vosburgh E; Levine AJ; Cong L; Xu EY J Vis Exp; 2012 Aug; (66):e4218. PubMed ID: 22929519 [TBL] [Abstract][Full Text] [Related]
5. Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines. Yu H; Kim DJ; Choi HY; Kim SM; Rahaman MI; Kim YH; Kim SW BMC Cancer; 2021 Sep; 21(1):1049. PubMed ID: 34560848 [TBL] [Abstract][Full Text] [Related]
6. Exploring the multifaceted antitumor activity of axitinib in lung carcinoids. Oldani M; Cantone MC; Gaudenzi G; Carra S; Dicitore A; Saronni D; Borghi MO; Lombardi A; Caraglia M; Persani L; Vitale G Front Endocrinol (Lausanne); 2024; 15():1433707. PubMed ID: 39050569 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro. Sacewicz M; Lawnicka H; Siejka A; Stepień T; Krupiński R; Komorowski J; Stepień H Cancer Lett; 2008 Sep; 268(1):120-8. PubMed ID: 18486324 [TBL] [Abstract][Full Text] [Related]
8. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance. Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679 [TBL] [Abstract][Full Text] [Related]
9. Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance. Brodaczewska KK; Bielecka ZF; Maliszewska-Olejniczak K; Szczylik C; Porta C; Bartnik E; Czarnecka AM Oncol Rep; 2019 Nov; 42(5):1878-1892. PubMed ID: 31545459 [TBL] [Abstract][Full Text] [Related]
10. 3D microengineered vascularized tumor spheroids for drug delivery and efficacy testing. Ahn J; Kim DH; Koo DJ; Lim J; Park TE; Lee J; Ko J; Kim S; Kim M; Kang KS; Min DH; Kim SY; Kim Y; Jeon NL Acta Biomater; 2023 Jul; 165():153-167. PubMed ID: 36243378 [TBL] [Abstract][Full Text] [Related]
11. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. Herrmann R; Fayad W; Schwarz S; Berndtsson M; Linder S J Biomol Screen; 2008 Jan; 13(1):1-8. PubMed ID: 18040052 [TBL] [Abstract][Full Text] [Related]
12. Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids. Senkowski W; Jarvius M; Rubin J; Lengqvist J; Gustafsson MG; Nygren P; Kultima K; Larsson R; Fryknäs M Cell Chem Biol; 2016 Nov; 23(11):1428-1438. PubMed ID: 27984028 [TBL] [Abstract][Full Text] [Related]
13. Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides. Wang J; Zhang X; Li X; Zhang Y; Hou T; Wei L; Qu L; Shi L; Liu Y; Zou L; Liang X Sci Rep; 2016 Apr; 6():24772. PubMed ID: 27098119 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft. Ma YH; Wang SY; Ren YP; Li J; Guo TJ; Lu W; Zhou TY Acta Pharmacol Sin; 2019 Feb; 40(2):243-256. PubMed ID: 29773888 [TBL] [Abstract][Full Text] [Related]
16. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264 [TBL] [Abstract][Full Text] [Related]
17. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Nunes AS; Barros AS; Costa EC; Moreira AF; Correia IJ Biotechnol Bioeng; 2019 Jan; 116(1):206-226. PubMed ID: 30367820 [TBL] [Abstract][Full Text] [Related]
18. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. Voissiere A; Jouberton E; Maubert E; Degoul F; Peyrode C; Chezal JM; Miot-Noirault É PLoS One; 2017; 12(7):e0181340. PubMed ID: 28704566 [TBL] [Abstract][Full Text] [Related]
19. Formation of multicellular tumor spheroids induced by cyclic RGD-peptides and use for anticancer drug testing in vitro. Akasov R; Zaytseva-Zotova D; Burov S; Leko M; Dontenwill M; Chiper M; Vandamme T; Markvicheva E Int J Pharm; 2016 Jun; 506(1-2):148-57. PubMed ID: 27107900 [TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology. Opriţa A; Dobrescu MA; Manea EV; Popescu ŞO; Sevastre AS; Pîrvu AS; Buzatu IM; Tache DE Rom J Morphol Embryol; 2023; 64(2):173-180. PubMed ID: 37518874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]